Your browser doesn't support javascript.
loading
Something wicked this way comes: What health care providers need to know about Candida auris.
Schwartz, I S; Smith, S W; Dingle, T C.
Afiliación
  • Schwartz IS; Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB.
  • Smith SW; Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB.
  • Dingle TC; Division of Diagnostic and Applied Microbiology, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB.
Can Commun Dis Rep ; 44(11): 271-276, 2018 Nov 01.
Article en En | MEDLINE | ID: mdl-30996689
Candida auris is a fungal pathogen that recently emerged and rapidly spread around the globe. It is now in Canada. C. auris can cause invasive disease with high mortality rates, is frequently resistant to one or more classes of antifungals, and can be difficult to identify in some clinical microbiology laboratories. C. auris can also involve prolonged colonization of patients' skin and contamination of surrounding environments, resulting in nosocomial outbreaks in hospitals and long-term care facilities. Clinicians, infection prevention and control practitioners and public health officials should be aware of how to mitigate the threat posed by this pathogen. Index cases of C. auris should be suspected in patients with invasive candidiasis and recent hospitalization in global regions where C. auris is prevalent, as well as in patients who fail to respond to empiric antifungal therapy and from whom unidentified or unusual Candida species have been isolated. If a case of C. auris infection or colonization is identified or suspected, the following should take place: notification of local public health authorities and infection prevention and control practitioners; placement of colonized or infected patients in single rooms with routine contact precautions; daily and terminal environmental disinfection with a sporicidal agent; contact tracing and screening for C. auris transmission; and referral of suspicious or confirmed isolates to provincial laboratories. Patients with symptomatic disease should be treated with an echinocandin pending the results of antifungal susceptibility testing, preferably in consultation with an infectious disease specialist. Through the vigilance of front-line health care workers and microbiologists, robust infection prevention and control practices, and local and national surveillance efforts, C. auris can be detected quickly, infections managed and transmissions prevented to protect patients in our health care system.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_recursos_humanos_saude Idioma: En Revista: Can Commun Dis Rep Asunto de la revista: DOENCAS TRANSMISSIVEIS / EPIDEMIOLOGIA Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_recursos_humanos_saude Idioma: En Revista: Can Commun Dis Rep Asunto de la revista: DOENCAS TRANSMISSIVEIS / EPIDEMIOLOGIA Año: 2018 Tipo del documento: Article
...